Agilent Technologies, Inc.

Agilent Technologies, Inc.

A
Agilent Technologies, Inc.US flagNew York Stock Exchange
130.26
USD
-1.20
- -
36.79BMarket Cap
Agilent Technologies, Inc.
A
(New York Stock Exchange)

Recent

price

130.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
15.69
19.06
19.71
11.42
12.16
12.13
12.89
13.89
15.31
16.44
17.28
20.79
22.9
23.24
22.45
24.46
25.55
Revenue per Share
1.97
2.92
3.31
2.15
1.65
1.2
1.42
2.12
0.98
3.41
2.33
3.98
4.19
4.22
4.44
4.59
5
Basic EPS, GAAP
1.72
3.09
2.97
2.81
1.58
1.24
2.01
2.21
2.83
2.75
2.6
4.26
3.41
5.01
4.73
4.06
3.84
Free Cash Flow per Basic Share
- -
- -
0.3
0.46
0.53
0.4
0.46
0.53
0.6
0.66
0.72
0.78
0.84
0.9
0.94
0.99
1.01
Dividend per Share
9.94
12.86
15.84
17.83
19.44
16.78
18.7
-0.38
-1.04
-0.05
0.27
1.15
1.09
2.67
2.6
4.9
5.99
Book Value per Share
3.71
6.69
3.09
3.89
6.45
4.08
4.03
5.8
3.45
0.15
1.42
1.42
1.78
4.8
3.01
6.42
7.88
Tangible Book Value per Share
347
347
348
341
333
333
326
322
321
314
309
304
299
294
290
284
283
Basic Weighted Avg Shares
5,444
6,615
6,858
3,894
4,048
4,038
4,202
4,472
4,914
5,163
5,339
6,319
6,848
6,833
6,510
6,948
7,232
Sales/Revenue/Turnover
10.4
16.19
16.32
9.91
10.35
12.93
14.64
18.05
18.4
18.23
15.85
21.32
23.63
19.76
22.86
21.29
21.5
Operating Margin (%)
202
253
301
372
384
253
246
212
210
238
308
321
317
271
257
288
277
Depreciation Expense
684
1,012
1,153
734
549
401
462
684
316
1,071
719
1,210
1,254
1,240
1,289
1,303
1,414
Net Income, GAAP
1.16
1.94
- -
23.21
- -
8.75
15.07
14.82
66.6
- -
14.61
11.03
16.62
7.39
15.25
9.2
10.51
Effective Tax Rate (%)
12.56
15.3
16.81
18.85
13.56
9.93
10.99
15.3
6.43
20.74
13.47
19.15
18.31
18.15
19.8
18.75
19.55
Profit Margin (%)
3,086
3,732
2,736
3,381
3,817
2,710
2,690
2,906
2,677
1,109
1,948
2,091
1,917
2,583
2,064
2,247
2,494
Working Capital
2,190
1,932
2,112
2,699
1,663
1,655
1,904
1,801
1,799
1,791
2,284
2,729
2,733
2,735
3,345
3,050
3,051
LT Debt
3,236
4,316
5,185
5,289
5,304
4,170
4,246
4,835
4,571
4,748
4,873
5,389
5,305
5,845
5,898
6,741
7,122
Total Equity
9.04
15.64
- -
3.82
- -
7.45
8.72
10.58
4.57
- -
10.04
15.61
16.66
15.01
14.11
13.86
13.84
Return on Invested Capital (%)
12.14
15.88
- -
9.8
- -
6
6.86
15.19
20.29
- -
32.5
46.43
42.88
40.14
35.77
31.61
31.88
Return on Capital (%)
22.01
25.58
23.12
12.67
8.75
6.65
7.91
- -
- -
- -
- -
556.32
369.91
223.02
167.62
121.49
108.35
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Oct'25
Jan'26
Apr'26
ST Debt
304
304
304
LT Borrowings
3,050
3,050
3,051
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
283
283
282
Market Capitalization
41,603
37,980
32,701

Working Capital

FRC

in mil. unless spec.
Oct'25
Jan'26
Apr'26
Total Current Assets
4,594
4,615
4,763
Cash, Cash Equivalents & STI
1,789
1,758
1,807
Accounts Receivable, Net
1,487
1,521
1,498
Inventories
1,025
1,059
1,089
Total Current Liabilities
2,347
2,234
2,269
Payables & Accruals
976
951
913
ST Debt
304
304
304
Deferred Revenue
624
682
665

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.11%
6.88%
14.29%
Free Cash Flow
14.42%
12.36%
-16.1%
Net Income, GAAP
29.14%
15.17%
1.09%
Sales/Revenue/Turnover
5.74%
5.7%
6.73%
Total Cash Common Dividend
7.86%
4.91%
2.92%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,658
1,573
1,578
1,701
6,510
2025
1,681
1,668
1,738
1,861
6,948
2026
1,798
1,835
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.19
1.05
0.97
1.23
4.44
2025
1.12
0.75
1.18
1.53
4.59
2026
1.08
1.2
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.24
0.23
0.24
0.94
2025
0.25
0.25
0.25
0.25
0.99
2026
0.25
0.26
- -
- -
- -
Business
Agilent Technologies, Inc. (NYSE: A) provides instruments, software, services, and consumables for the life sciences, diagnostics, chemical analysis, and applied markets. The company offers a broad portfolio of products and services including gas chromatography and liquid chromatography systems; mass spectrometry and molecular spectroscopy instruments; microarrays, automation, and informatics solutions; bioreagents, FISH probes, target enrichment, and next-generation sequencing tools; immunohistochemistry and pathology solutions; genomics, proteomics, and cell analysis platforms; sample preparation, GC and HPLC columns, spectrometry supplies, and consumables; as well as laboratory management services encompassing enterprise asset management, compliance support, training, and CrossLab virtual assist for remote technical support. Headquartered in Santa Clara, California, Agilent operates globally in more than 100 countries, serving analytical laboratories, pharmaceutical, biopharma, clinical diagnostics, environmental, forensics, food, energy, academia, and government sectors; it was spun off from Hewlett-Packard in 1999. Recent developments include the completion of its $925 million acquisition of BIOVECTRA, Inc., a Canada-based contract development and manufacturing organization specializing in biologics, active pharmaceutical ingredients, sterile fill-finish, plasmid DNA, mRNA, lipid nanoparticles, antibody-drug conjugates, and high-potency APIs, enhancing Agilent's CDMO capabilities for gene editing and therapeutics; a $7 million investment to modernize R&D and applications labs in Delaware; the launch of the Agilent Innovation Hub in partnership with the University of Melbourne; a strategic collaboration with SeqOne for liquid biopsy data analysis in oncology; and expansions such as a $725 million nucleic acid therapeutics facility in Frederick, Colorado, alongside new product launches driving growth in specialty CDMO services for siRNA and GLP-1 modalities.

Company News

APIChatGPT
  • Agilent Increases Its Investment in HALO X-ray Technologies

  • Dividend Champion, Contender, And Challenger Highlights: Week Of July 19

  • Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

  • Agilent Strengthens Biopharma Growth Prospects With AI Expansion

  • Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

  • Alpha and Omega Semiconductor Unveils AmpStack™ Packaging: A Leap Forward in MOSFET Power Density

  • Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

  • Why Is Agilent (A) Up 0.1% Since Last Earnings Report?

  • Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies

  • Agilent Completes Acquisition of Biocare Medical

  • Canadian Apartment REIT: A 4.5% Dividend Yield With Ample Coverage

  • Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

  • Lost Money on Verra Mobility Corporation (VRRM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

  • GPK Deadline Alert: Levi & Korsinsky Reminds Graphic Packaging Holding Company (GPK) Investors of Securities Class Action Deadline on July 6, 2026

  • UMH PROPERTIES, INC. WELCOMES THE 21ST CENTURY ROAD TO HOUSING ACT: A MAJOR BOOST FOR AFFORDABLE MANUFACTURED HOUSING

  • Tradeweb Announces Date for Second Quarter 2026 Financial Results

  • The Presidio Group Exclusively Advised Fletcher Jones Automotive Group on the Sale of Porsche, Mercedes-Benz and Audi dealerships in Northern California to AutoNation

  • MSFT Shareholder Alert: Microsoft Corporation Securities Class Action Lawsuit - Investors Should Contact SueWallSt

  • Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

  • Is the Options Market Predicting a Spike in Agilent Technologies Stock?